The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Johan Lochen, Erik Penser Bank. Phone: +46 8 463 80 00. Erik Penser Bank equity research

Felicia Rittemar, Vator Securities, Phone: +46 8 5333 2737. Vator Securities equity research

  Quarterly Report 2 21/22, March 30, 2022
Two weeks ago, we announced the opening of the first contracted clinic in our Phase 3 trial for enrollment of patients. This is a significant milestone for Diamyd Medical. The trial is the result of combining scientific advances in Type 1 Diabetes (T1D) with findings from numerous clinical trials evaluating the therapeutic vaccine Diamyd®. Most importantly, the DIAGNODE-3 trial design is based on large scale data analyses that support the statistical robustness and scientific rational of this pivotal trial, increasing the likelihood of clinical,...
We are proud that Diamyd Medical is at the forefront of the biotech industry with the first ever precision medicine Phase 3 trial in Type 1 Diabetes.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
12
May 19, 2022
Erik Penser Banks Bolagsdag
vd Ulf Hannelius presenterar på Erik Penser Banks Bolagsdag. Presentationen sänds live kl. 09:35 CET.
June 3 − June 7, 2022
ADA 82nd Scientific Sessions
June 13 − June 16, 2022
BIO2022
June 22, 2022
Quarterly Report III
Quarterly Report 3 2021/2022
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 31, 2022

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 10 242 771 13.32 10.25
Essen-Möller, Anders 2 556 223 5 313 040 10.23 30.90
Lindkvist, Bertil 6 240 000 8.11 6.24
Nordnet Pension 2 545 590 3.31 2.55
Swedbank Försäkring 903 657 1.17 0.90
Konstruktions o Försäljningsaktiebolag 725 000 0.94 0.73
Arandi Development AB 505 000 0.66 0.51
Lindberg, Mikael 501 487 0.65 0.50
Relbo AB 468 500 0.61 0.47
Essen-Möller, Maria-Teresa 463 998 0.60 0.46
Remaining shareholders 46 461 673 60.40 46.49
Total 2 556 223 74 370 716 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS